Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study
EClinicalMedicine(2023)
摘要
Incyte Corporation.
更多查看译文
关键词
Follicular lymphoma,Parsaclisib,PI3K inhibitor,Non-Hodgkin lymphoma
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要